LTI
VRTX icon

Laffer Tengler Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Laffer Tengler Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,926
Closed -$1.75M – 197
2025
Q2 		$1.75M Sell
3,926
-227
-5% -$105K 0.31% 85
2025
Q1 		$2.01M Buy
4,153
+19
+0.5% +$8.85K 0.43% 73
2024
Q4 		$1.66M Buy
4,134
+1,260
+44% +$584K 0.33% 80
2024
Q3 		$1.34M Buy
2,874
+82
+3% +$39.4K 0.27% 89
2024
Q2 		$1.31M Buy
2,792
+539
+24% +$234K 0.28% 91
2024
Q1 		$942K Buy
2,253
+2,246
+32,086% +$949K 0.24% 90
2023
Q4 		$2.85K Buy
+7
New +$2.59K ﹤0.01% 363
2022
Q2 		– Sell
-10
Closed -$2.61K – 430
2022
Q1 		$2.61K Hold
10
– – ﹤0.01% 357
2021
Q4 		$2.2K Hold
10
– – ﹤0.01% 338
2021
Q3 		$1.81K Buy
+10
New +$1.95K ﹤0.01% 439

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Laffer Tengler Investments's VRTX Position: Q3 2025 in Review

Laffer Tengler Investments sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 3,926 shares — an estimated $1.75M sold.

Laffer Tengler Investments first reported a position in VRTX in Q3 2021 and held it in 10 quarters. The position peaked at $2.01M in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Laffer Tengler Investments reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Laffer Tengler Investments sold 3,926 Vertex Pharmaceuticals shares in Q3 2025, an estimated $1.75M.
  • Laffer Tengler Investments first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 10 quarters.
  • Laffer Tengler Investments's Vertex Pharmaceuticals position peaked at $2.01M in Q1 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Laffer Tengler Investments's 13F filing for Q3 2025, filed 12 Nov 2025.